TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06256848

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation treatment
Description: Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment
Description: Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myofascial Release Therapy
Description: Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
Study: NCT04407767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case Formulation plus Cognitive Processing Therapy
Description: The CF approach alters the CPT protocol in two ways: expanding the protocol to intentionally and systematically address impairment in functioning, and enhancing the providers' latitude to navigate challenges to optimal therapy outcomes (COTOS). CF-CPT begins with a formal CF assessment session; elements of CF are then integrated throughout CPT. CF modifications to the original CPT protocol occur in each session by intentionally attending to cognitions that are impeding the patient's functional recovery. The second modification includes enhancing the provider's latitude to diverge from the protocol when clinically wise. CF-CPT provides guidance around the identification, monitoring and management of COTOs, and, importantly, the expedient return to the CPT protocol with continued attention to COTOs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: CPT is a brief therapy for PTSD predominantly based on cognitive theory. Traditionally delivered over 12 one-hour sessions weekly or twice weekly, CPT is now variable length depending on patient's recovery from PTSD. CPT is delivered in three phases: education, processing, and challenging and focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Changing dysfunctional beliefs alters negative emotions emanating from those beliefs.
Study: NCT06222892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camlipixant
Description: Camlipixant will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camlipixant
Description: Camlipixant will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camlipixant
Description: Camlipixant will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camlipixant
Description: Camlipixant will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camlipixant
Description: Camlipixant will be administered.
Study: NCT05844917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: Ultrasound detection of subclinical arthritis among Patients With SLE
Study: NCT05486078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD Tissue Collagen Medical Device
Description: The Experimental Group will be treated with 2-mL volume ultrasound-guided infiltration of: MD-Tissue (GUNA, Milan-Italy). Composition for 2 ml: collagen 100 micrograms Subjects will be treated with No.1 infiltration per week for 3 consecutive weeks. The infiltrations will be performed in an echoguided mode.~MD-Tissue Collagen Medical Device will be infiltrated into the trochanteric bursa and at the level of the tendons of the gluteus minimus and gluteus medius, particularly at the level of the most degenerated insertional areas.
Study: NCT06063473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifarotene Cream 0.005%
Description: The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
Study: NCT04380610

Intervention type: DIAGNOSTIC_TEST
Intervention: iohexol GFR
Description: We will perform mGFR in 400 SCA patients

Intervention type: DIAGNOSTIC_TEST
Intervention: iohexol GFR
Description: We will perform mGFR in 400 SCA patients
Study: NCT05839834

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: RNA sequencing of peripheral blood cells

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: RNA sequencing of peripheral blood cells
Study: NCT06063473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)
Description: The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
Study: NCT06234904

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBR733 Cell Injection
Description: The minimum initial dose is 5.0×10\^9 cells and then escalate to 7.5×10\^9 cells and 10.0×10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 8 of each cycle.
Study: NCT04889274

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine
Description: COVID-19 vaccine as offered by NHS England

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine
Description: COVID-19 vaccine as offered by NHS England

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: COVID-19 vaccine
Description: COVID-19 vaccine as offered by NHS England

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 vaccine
Description: COVID-19 vaccine as offered by NHS England

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Concentrate beetroot Juice
Description: Beetroot juice containing approximately 5mmol/l nitrate

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate-deplete beetroot juice
Description: Beetroot juice with nitrate removed
Study: NCT05580120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online-supervised exercise group
Description: Participants in the online-supervised exercise group were provided with an online-supervised exercise program by using the video conferencing method three times a week for 6 weeks on the Zoom application. The exercise program was carried out synchronously

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unsupervised-exercise training group
Description: The unsupervised-exercise training group was informed about how to do the same exercises by another researcher, a nurse academician, on the online platform by using the lecturing method. Each training intervention took approximately 30 minutes.
Study: NCT05374486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroExo co-robot neurorehabilitation system
Description: In this longitudinal study, adult subjects with hemiparesis due to chronic stroke will receive robotic-assisted upper-arm training through an EEG-based BMI control of robotic exoskeleton to study the changes in upper extremity motor function, cortical plasticity (using the EEG). After one screening visit, two baseline visits for EEG signal screens, six onsite training sessions will be provided with the NeuroExo system, followed by 60 home therapy sessions (2 sessions per day, 5 days per week for 6 weeks). If the participant have completed at least 50 sessions of neurotherapy at home, the participant will complete a set of measurements to assess function of the affected upper arm and brain activity within 3 days after the last session for post-assessment visit, and one-month post follow-up session. The total amount of time for this study is 16-20 weeks.
Study: NCT05095935

Intervention type: OTHER
Intervention: N/A observational registry
Description: N/A observational registry

Intervention type: OTHER
Intervention: N/A observational registry
Description: N/A observational registry

Intervention type: OTHER
Intervention: N/A observational registry
Description: N/A observational registry
Study: NCT05872126

Intervention type: PROCEDURE
Group type: OTHER
Intervention: VATS-Surgical pleurodesis
Description: VATS drainage and surgical abrasion.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tube Drainage
Description: Tube drainage for malignant pleural effusion
Study: NCT05271487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-Step Botanical Skin Care Regimen
Description: The intervention includes 7 different topical products:~1. Cleanser~2. Toner~3. Oil Control Cream~4. Exfoliating Facial Scrub~5. Clay Mask~6. Acne Spot Treatment~7. Body Scrub
Study: NCT04764890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Electroacupuncture in several point
Study: NCT04811092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04764890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Manual therapy in the lower spine.
Study: NCT05974163

Intervention type: DIAGNOSTIC_TEST
Intervention: radiomic of CT
Description: Computed Tomography (CT) is often an important examination method for emergency diagnosis because of its fast examination speed and accurate localization acute respiratory distress syndrome.

Intervention type: DIAGNOSTIC_TEST
Intervention: radiomic of CT
Description: Computed Tomography (CT) is often an important examination method for emergency diagnosis because of its fast examination speed and accurate localization acute respiratory distress syndrome.

Intervention type: DIAGNOSTIC_TEST
Intervention: radiomic of CT
Description: Computed Tomography (CT) is often an important examination method for emergency diagnosis because of its fast examination speed and accurate localization acute respiratory distress syndrome.
Study: NCT05763147

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Access Device Flushing
Description: locking and flushing the end of catheter line at the intervals of different drug treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous Access Device Flushing
Description: locking and flushing the end of catheter line at the intervals of different drug treatment.
Study: NCT06328491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Protein Kinase Inhibitor
Study: NCT04093505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin 147
Description: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemtuzumab Ozogamicin 147
Description: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin 1
Description: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemtuzumab Ozogamicin 1
Description: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib
Description: Consolidation \& Maintenance therapy Glasdegib 100mg on days 4 to 27

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib
Description: Consolidation \& Maintenance therapy Glasdegib 100mg on days 4 to 27

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Consolidation \& Maintenance therapy Placebo 100mg on days 4 to 27

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Consolidation \& Maintenance therapy Placebo 100mg on days 4 to 27
Study: NCT04764890

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Manual therapy in the lower spine.
Study: NCT05505994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001 A mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWP16001 Placebo
Description: DWP16001 Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin Placebo
Description: Dapagliflozin Placebo tablet
Study: NCT05837169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Description: The control group will be assessed with the study surveys at baseline, will not receive MBSR intervention for the following 8 weeks, and will subsequently be reassessed with the study surveys at the same time points as the intervention group. At the end of the recruitment and follow-up of all the participants, the study will end and the control group will be able to receive the MBSR intervention free of charge according to the preference of the participants.
Study: NCT06422754

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Becure GmbH
Description: Becure Balance System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Becure GmbH
Description: Becure Balance System
Study: NCT06156293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral prevention program for insomnia (CBP-I)
Description: CBP-I will be provided to participants once their districts are exposed.
Study: NCT05909800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenofibrate
Description: Administred orally, once daily, for 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administred orally, once daily, for 12 months.
Study: NCT06530693

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OPUS-i algorithm
Description: A novel pre-hospital algorithm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OPUS-i algorithm
Description: A novel pre-hospital algorithm.
Study: NCT05076500

Intervention type: PROCEDURE
Intervention: Biopsy and blood sample collection
Description: A pre-treatment diagnostic biopsy sample plus 1 mandatory biopsy (during/post-radiotherapy \[irradiated site\]) will be collected from each participant.~Matched blood samples will be collected from participants at baseline, during/post-radiotherapy, and if radiotherapy continues after the on-treatment biopsy is taken, an additional end of treatment blood sample will be collected.

Intervention type: PROCEDURE
Intervention: Biopsy and blood sample collection
Description: A pre-treatment diagnostic biopsy sample plus 1 mandatory biopsy (during/post-radiotherapy \[irradiated site\]) will be collected from each participant.~Matched blood samples will be collected from participants at baseline, during/post-radiotherapy, and if radiotherapy continues after the on-treatment biopsy is taken, an additional end of treatment blood sample will be collected.

Intervention type: PROCEDURE
Intervention: Biopsy and blood sample collection
Description: A pre-treatment diagnostic biopsy sample plus 1 mandatory biopsy (during/post-radiotherapy \[irradiated site\]) will be collected from each participant.~Matched blood samples will be collected from participants at baseline, during/post-radiotherapy, and if radiotherapy continues after the on-treatment biopsy is taken, an additional end of treatment blood sample will be collected.

Intervention type: PROCEDURE
Intervention: Biopsy and blood sample collection
Description: A pre-treatment diagnostic biopsy sample plus 1 mandatory biopsy (during/post-radiotherapy \[irradiated site\]) will be collected from each participant.~Matched blood samples will be collected from participants at baseline, during/post-radiotherapy, and if radiotherapy continues after the on-treatment biopsy is taken, an additional end of treatment blood sample will be collected.

Intervention type: PROCEDURE
Intervention: Biopsy and blood sample collection
Description: A pre-treatment diagnostic biopsy sample plus 1 mandatory biopsy (during/post-radiotherapy \[irradiated site\]) will be collected from each participant.~Matched blood samples will be collected from participants at baseline, during/post-radiotherapy, and if radiotherapy continues after the on-treatment biopsy is taken, an additional end of treatment blood sample will be collected.

Intervention type: PROCEDURE
Intervention: Biopsy and blood sample collection
Description: A pre-treatment diagnostic biopsy sample plus 1 mandatory biopsy (during/post-radiotherapy \[irradiated site\]) will be collected from each participant.~Matched blood samples will be collected from participants at baseline, during/post-radiotherapy, and if radiotherapy continues after the on-treatment biopsy is taken, an additional end of treatment blood sample will be collected.
Study: NCT05167539

Intervention type: PROCEDURE
Intervention: Aortic valve surgery
Description: mechanical aortic valve replacement versus ross procedure and stentless bioprothesis

Intervention type: PROCEDURE
Intervention: Aortic valve surgery
Description: mechanical aortic valve replacement versus ross procedure and stentless bioprothesis
Study: NCT05289882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PASS Program Condition:
Description: Participants randomized to this condition will be invited to take part in weekly ball hockey games (once per week), that will last approximately 60 minutes, and will be followed by opportunities to socially connect afterwards. The results of our feasibility study indicated that the PASS program acted as an important conduit to direct participants to other support services and resources (e.g., counseling, career transition centre, employment, education). Military veteran men are often reluctant to access such supports, especially if they attach stigma to such services (e.g., mental health services). At each site, a military veteran will be trained as a facilitator to operate as a conduit to refer participants to the relevant support services and agencies.
Study: NCT05011435

Intervention type: DEVICE
Intervention: web-application for burnout
Description: Use of burnout advisor web-application for detection of professional burnout
Study: NCT04992507

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anesthesia Procedure
Description: Given TIVA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia Procedure
Description: Given inhaled volatile anesthetics

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection
Description: Undergo surgical resection
Study: NCT06515535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid
Description: Topical tranexamic acid will be applied after placental delivery on the placental bed for 5 minutes by using a sterile towel soaked with 2g tranexamic acid (Kapron, Amoun, Cairo, Egypt) (4 ampules 500ug) diluted in 100ml of sodium chloride 0.9%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous tranexamic acid
Description: Intravenous tranexamic acid will be given in the form of an IV infusion of 1g of tranexamic acid (2 ampules 500ug) diluted with 20 ml of 5% glucose administered just after delivery of the fetus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid
Description: Intravenous tranexamic acid will be given in the form of an IV infusion of 1g of tranexamic acid (2 ampules 500ug) diluted with 20 ml of 5% glucose administered just after delivery of the fetus.
Study: NCT04743570

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Active drug/placebo is given for the first 5 days of admission.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylnaltrexone treatment
Description: Active drug/placebo is given for the first 5 days of admission.
Study: NCT05143502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast is a leukotrienes antagonist which has proven efficacious in chronic inflammatory conditions of the airways, including allergic rhinitis, asthma, and aspirin-exacerbated respiratory disease (AERD), all diseases that often coexist with CRSwNP.~We will use oral Montelukast (montelukast 10 mg, once a day) for 3 monthes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral Prednisolone 40 mg/day for two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral Prednisolone 40 mg/day for two weeks.
Study: NCT06354556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1893 tablet
Description: HRS-1893 tablet single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil tablet
Description: Verapamil tablet 80 mg tid
Study: NCT05243888

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: self-sampling
Description: eligible women receive at their home address a self-sampling kit in addition to the conventional invitation letter

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: self-sampling
Description: eligible women receive at their home address a self-sampling kit in addition to the conventional invitation letter